| Year |
Citation |
Score |
| 2024 |
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, et al. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Jama Network Open. 7: e2437871. PMID 39374015 DOI: 10.1001/jamanetworkopen.2024.37871 |
0.501 |
|
| 2024 |
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, ... Goldkorn A, et al. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology. PMID 39003201 DOI: 10.1016/j.eururo.2024.06.018 |
0.301 |
|
| 2024 |
Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer and Prostatic Diseases. PMID 38424319 DOI: 10.1038/s41391-024-00813-3 |
0.319 |
|
| 2023 |
Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, et al. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. European Urology. PMID 37085425 DOI: 10.1016/j.eururo.2023.03.036 |
0.428 |
|
| 2023 |
Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, ... ... Goldkorn A, et al. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202394. PMID 36996380 DOI: 10.1200/JCO.22.02394 |
0.408 |
|
| 2022 |
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. Molecular Cancer Therapeutics. PMID 36198026 DOI: 10.1158/1535-7163.MCT-22-0020 |
0.384 |
|
| 2022 |
Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Current Oncology Reports. PMID 35575959 DOI: 10.1007/s11912-022-01278-0 |
0.347 |
|
| 2022 |
Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, et al. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102517. PMID 35446628 DOI: 10.1200/JCO.21.02517 |
0.408 |
|
| 2022 |
Lu YT, Xu T, Iqbal M, Hsieh TC, Luo Z, Liang G, Farnham PJ, Rhie SK, Goldkorn A. FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers. 14. PMID 35406487 DOI: 10.3390/cancers14071717 |
0.335 |
|
| 2022 |
Xu T, Junge JA, Delfarah A, Lu YT, Arnesano C, Iqbal M, Delijani K, Hsieh TC, Hodara E, Mehta HH, Cohen P, Graham NA, Fraser SE, Goldkorn A. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Scientific Reports. 12: 5518. PMID 35365706 DOI: 10.1038/s41598-022-09438-9 |
0.307 |
|
| 2022 |
Morrison G, Buckley J, Ostrow D, Varghese B, Cen SY, Werbin J, Ericson N, Cunha A, Lu YT, George T, Smith J, Quinn D, Duddalwar V, Triche T, Goldkorn A. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences. 23. PMID 35269713 DOI: 10.3390/ijms23052571 |
0.334 |
|
| 2021 |
Goldkorn A, Tangen CM, Plets M, Morrison GJ, Cunha A, Xu T, Pinski J, Ingles SA, Triche TJ, Harzstark A, Kohli M, MacVicar GR, Vaena D, Crispino AW, McConkey DJ, et al. Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33500355 DOI: 10.1158/1078-0432.CCR-20-3587 |
0.478 |
|
| 2020 |
Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. International Journal of Cancer. PMID 32037533 DOI: 10.1002/Ijc.32915 |
0.576 |
|
| 2020 |
Xu T, Li HT, Wei J, Li M, Hsieh TC, Lu YT, Lakshminarasimhan R, Xu R, Hodara E, Morrison G, Gujar H, Rhie SK, Siegmund K, Liang G, Goldkorn A. Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype. International Journal of Cancer. PMID 32017074 DOI: 10.1002/Ijc.32904 |
0.489 |
|
| 2020 |
Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain MHA, Gupta S, Zhang J, Twardowski P, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel. Journal of Clinical Oncology. 38: 5523-5523. DOI: 10.1200/Jco.2020.38.15_Suppl.5523 |
0.39 |
|
| 2020 |
Goldkorn A, Tangen C, Plets M, Morrison G, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara P, Hussain MHA, et al. Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide. Journal of Clinical Oncology. 38: 5506-5506. DOI: 10.1200/Jco.2020.38.15_Suppl.5506 |
0.547 |
|
| 2020 |
Lerner SP, McConkey DJ, Tangen C, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs RC, Gustafson D, et al. Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695). Journal of Clinical Oncology. 38: 5028-5028. DOI: 10.1200/Jco.2020.38.15_Suppl.5028 |
0.34 |
|
| 2020 |
Morrison GJ, Buckley J, Ostrow DG, Varghese B, Ericson N, Cen S, Cunha A, Lu Y, George T, Smith J, Quinn D, Duddalwar V, Triche T, Goldkorn A. Abstract 5379: Non-invasive profiling of advanced prostate cancer via multi-parametric liquid biopsy and radiomics Clinical Trials. 80: 5379-5379. DOI: 10.1158/1538-7445.Am2020-5379 |
0.494 |
|
| 2019 |
Lu YT, Delijani K, Mecum A, Goldkorn A. Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Management and Research. 11: 5271-5291. PMID 31239778 DOI: 10.2147/Cmar.S170380 |
0.479 |
|
| 2019 |
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. PMID 31227432 DOI: 10.1016/J.Clgc.2019.02.010 |
0.512 |
|
| 2019 |
Hodara E, Morrison G, Cunha AT, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo BS, Ting MJ, Cotter PD, Moore MW, Gunn S, ... ... Goldkorn A, et al. Multi-parametric liquid biopsy analysis in metastatic prostate cancer. Jci Insight. PMID 30702443 DOI: 10.1172/Jci.Insight.125529 |
0.524 |
|
| 2019 |
Lu Y, Gooden GC, Tew BY, Buckley D, Siegmund K, Daneshmand S, Salhia B, Goldkorn A. Cell-free DNA (cfDNA) whole genome bisulfite sequencing in patients with muscle-invasive bladder cancer patient treated with cystectomy with curative intent. Journal of Clinical Oncology. 37: 359-359. DOI: 10.1200/Jco.2019.37.7_Suppl.359 |
0.395 |
|
| 2019 |
Morrison G, Cunha A, Jojo N, Manojlovic Z, Xu Y, Robinson PS, Dorff TB, Quinn DI, Goldkorn A. Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: e16587-e16587. DOI: 10.1200/Jco.2019.37.15_Suppl.E16587 |
0.521 |
|
| 2019 |
Lu Y, Gooden GC, Tew BY, Buckley D, Siegmund K, Daneshmand S, Salhia B, Goldkorn A. Epigenomic profiling of plasma cell-free DNA (cfDNA) to predict bladder cancer recurrence after radical cystectomy. Journal of Clinical Oncology. 37: e14525-e14525. DOI: 10.1200/Jco.2019.37.15_Suppl.E14525 |
0.407 |
|
| 2019 |
Morris MJ, Heller G, Bryce AH, Armstrong AJ, Beltran H, Hahn OM, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Hillman DW, Taplin M, Ryan CJ, et al. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 5008-5008. DOI: 10.1200/Jco.2019.37.15_Suppl.5008 |
0.45 |
|
| 2019 |
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs RC, MacVicar GR, Bastos BR, Gustafson D, Plets M, et al. SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. Journal of Clinical Oncology. 37: 4506-4506. DOI: 10.1200/Jco.2019.37.15_Suppl.4506 |
0.363 |
|
| 2019 |
Xu T, Li H, Xu R, Wei J, Li M, Liang G, Goldkorn A. Abstract 4335: Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4335 |
0.422 |
|
| 2019 |
Lu Y, Gooden G, Tew BY, Buckley D, Siegmund K, Daneshmand S, Goldkorn A, Salhia B. Abstract 2274: Whole-genome bisulfite sequencing of cell-free DNA (cfDNA) in muscle-invasive bladder cancer patients to predict the risk of recurrence Cancer Research. 79: 2274-2274. DOI: 10.1158/1538-7445.Sabcs18-2274 |
0.414 |
|
| 2019 |
Xu T, Arnesano C, Delfarah A, Luo Z, Delijani K, Hodara E, Farnham P, Graham NA, Fraser SE, Goldkorn A. Abstract 5282: Transition to and from a cancer stem-like state is marked by rapid metabolic shifts that are observable in real time using fluorescence lifetime imaging microscopy (FLIM) Cancer Research. 79: 5282-5282. DOI: 10.1158/1538-7445.Am2019-5282 |
0.457 |
|
| 2018 |
Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Twardowski P, Quinn DI, Vogelzang NJ, Thompson I, Agarwal N. Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii275-viii276. PMID 32136632 DOI: 10.1093/Annonc/Mdy284.010 |
0.457 |
|
| 2018 |
Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treatment and Research Communications. 16: 18-23. PMID 31298998 DOI: 10.1016/J.Ctarc.2018.04.005 |
0.455 |
|
| 2018 |
Zainfeld D, Goldkorn A. Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. Cancer Treatment and Research. 175: 87-104. PMID 30168118 DOI: 10.1007/978-3-319-93339-9_4 |
0.538 |
|
| 2018 |
Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, et al. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 30128950 DOI: 10.1007/S00280-018-3672-Y |
0.418 |
|
| 2018 |
Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urologic Oncology. PMID 30115512 DOI: 10.1016/J.Urolonc.2018.06.008 |
0.326 |
|
| 2018 |
Morrison GJ, Goldkorn A. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Current Oncology Reports. 20: 35. PMID 29572775 DOI: 10.1007/S11912-018-0683-0 |
0.485 |
|
| 2018 |
Hodara E, Zainfeld D, Morrison G, Cunha A, Xu Y, Carpten JD, Danenberg PV, Dempsey PW, Usher J, DANENBERG K, Bischoff FZ, Khurana A, Cotter PD, Moore M, Gunn S, ... ... Goldkorn A, et al. Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 274-274. DOI: 10.1200/Jco.2018.36.6_Suppl.274 |
0.469 |
|
| 2018 |
Morrison G, Jojo N, Cunha A, Xu Y, Robinson PS, Dorff TB, Quinn DI, Goldkorn A. Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling. Journal of Clinical Oncology. 36: 271-271. DOI: 10.1200/Jco.2018.36.6_Suppl.271 |
0.482 |
|
| 2018 |
Guth AM, Salzmann-Sullivan M, Beaton C, Goldkorn A, Gibson EA, Kessler E, Lam E, Flaig T, Agarwal R, Schlaepfer IR. Abstract A021: CPT1A-mediated fat oxidation and its role in the immune response to prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A021 |
0.427 |
|
| 2017 |
Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045523 DOI: 10.1093/Annonc/Mdx348 |
0.537 |
|
| 2017 |
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, et al. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer. PMID 28579151 DOI: 10.1016/J.Clgc.2017.05.014 |
0.513 |
|
| 2017 |
Hugen CM, Zainfeld DE, Goldkorn A. Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. Frontiers in Oncology. 7: 6. PMID 28191452 DOI: 10.3389/Fonc.2017.00006 |
0.436 |
|
| 2017 |
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen SG, Kuhn P, Gross ME. Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 35: 167-167. DOI: 10.1200/Jco.2017.35.6_Suppl.167 |
0.377 |
|
| 2017 |
Morrison G, Sero V, Xu Y, Pinski J, Ingles S, Quinn D, Forcato C, Buson G, Webb C, Horvath K, Khurana A, Medoro G, Verma S, Moore M, Cotter P, ... ... Goldkorn A, et al. Abstract 1717: Orthogonal identification of circulating tumor cells (CTCs) using single cell low pass whole-genome sequencing (WGS) and copy-number alteration (CNA) analysis Cancer Research. 77: 1717-1717. DOI: 10.1158/1538-7445.Am2017-1717 |
0.439 |
|
| 2016 |
Xu Y, Goldkorn A. Telomere and Telomerase Therapeutics in Cancer. Genes. 7. PMID 27240403 DOI: 10.3390/Genes7060022 |
0.388 |
|
| 2016 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, ... ... Goldkorn A, et al. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. The Prostate. PMID 26771938 DOI: 10.1002/Pros.23151 |
0.549 |
|
| 2016 |
Quinn DI, Wei D, Massopust K, Ketchens C, Hu J, Goldkorn A, Aparicio A, Sadeghi S, Pinski JK, Averia M, Groshen SG, Dorff TB. Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1. Journal of Clinical Oncology. 34: 574-574. DOI: 10.1200/Jco.2016.34.2_Suppl.574 |
0.329 |
|
| 2016 |
Tang S, Dorff TB, Tsao-Wei DD, Massopust K, Ketchens C, Hu J, Goldkorn A, Sadeghi S, Pinski JK, Averia M, Groshen SG, Press MF, Schuckman AK, Quinn DI. Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10-4. Journal of Clinical Oncology. 34: 424-424. DOI: 10.1200/Jco.2016.34.2_Suppl.424 |
0.419 |
|
| 2016 |
Hugen CM, Ward P, Petterson J, Dubeau L, Dempsey PW, Hu BR, Xu T, Quinn DI, Goldkorn A. Targeted next generation sequencing (NGS) of matched primary tumor, metastasis, circulating tumor cells (CTCs), and cell-free DNA (cfDNA) in a patient with advanced prostate cancer (PC). Journal of Clinical Oncology. 34: e23057-e23057. DOI: 10.1200/Jco.2016.34.15_Suppl.E23057 |
0.517 |
|
| 2016 |
Pond GR, Sonpavde G, Plets M, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski P, Veldhuizen PJV, Agarwal N, et al. Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Journal of Clinical Oncology. 34: 5079-5079. DOI: 10.1200/Jco.2016.34.15_Suppl.5079 |
0.483 |
|
| 2016 |
Goldkorn A, Plets M, Agarwal N, Hussain M, Lara P, Vaena DA, MacVicar GR, Crispino T, Harzstark AL, Twardowski P, Tangen CM, Hugen CM, Xu T, Xu Y, Pinski JK, et al. Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 34: 11516-11516. DOI: 10.1200/Jco.2016.34.15_Suppl.11516 |
0.545 |
|
| 2016 |
Morrison G, Hugen C, Xu T, Xu Y, Tanya D, Quinn D, Sadeghi S, Goldkorn A. Abstract 3160: Circulating tumor cell enrichment and dielectric manipulation for ultra-pure cell recovery in advanced bladder cancer Cancer Research. 76: 3160-3160. DOI: 10.1158/1538-7445.Am2016-3160 |
0.503 |
|
| 2016 |
Xu T, Morrison G, Xu Y, Triche T, Buckley J, Goldkorn A. Abstract 1546: Differential gene expression analysis by NGS of primary tumor xenograft cells, circulating tumor cells, and metastasis cells purified from the same mouse hosts to identify drivers of cancer dissemination Cancer Research. 76: 1546-1546. DOI: 10.1158/1538-7445.Am2016-1546 |
0.496 |
|
| 2016 |
Hugen C, Morrison G, Gill P, El-Khoueiry A, Tsao-Wei D, Groshen S, Xu Y, Xu T, Kossari N, Kao B, Wei J, Rochefort H, Tai Y, Goldkorn A. Circulating tumor cell analysis in a first-in-human phase I study of sEphB4-HSA, an inhibitor of EphrinB2-EphB4 signaling European Journal of Cancer. 69: S126-S127. DOI: 10.1016/S0959-8049(16)32976-8 |
0.341 |
|
| 2015 |
Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, ... ... Goldkorn A, et al. Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute. 107. PMID 25972604 DOI: 10.1093/Jnci/Djv135 |
0.317 |
|
| 2015 |
Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, et al. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. International Journal of Cancer. Journal International Du Cancer. 136: 1856-62. PMID 25219358 DOI: 10.1002/Ijc.29212 |
0.523 |
|
| 2015 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen SG, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, ... ... Goldkorn A, et al. Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype. Journal of Clinical Oncology. 33: 29-29. DOI: 10.1200/Jco.2015.33.7_Suppl.29 |
0.557 |
|
| 2015 |
Hu B, Liu S, Xu Y, Dempsey P, Strauss W, Wentzel K, Xu T, Pinski J, Dorff T, Winer-Jones J, Quinn DI, Goldkorn A. Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors Cancer Research. 75: 1587-1587. DOI: 10.1158/1538-7445.Am2015-1587 |
0.527 |
|
| 2015 |
Liu Y, Xu T, Xu Y, Kang D, Xu L, Park J, Chang JHC, Zhang X, Goldkorn A, Tai YC. Isolation of circulating tumor cells by a magnesium-embedded filter Journal of Micromechanics and Microengineering. 25. DOI: 10.1088/0960-1317/25/10/104002 |
0.32 |
|
| 2015 |
Hu B, Fairey A, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins R, Den R, ... ... Goldkorn A, et al. MP37-19 AXIN2 EXPRESSION PREDICTS PROSTATE CANCER RECURRENCE AND MEDIATES AN INVASIVE, TUMORIGENIC PHENOTYPE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1282 |
0.508 |
|
| 2015 |
Hu B, Liu S, Xu Y, Dempsey P, Strauss W, Wentzel K, Xu T, Pinski J, Dorff T, Triche T, Winer Jones J, Gill I, Quinn D, Goldkorn A. MP37-06 TARGETED SEQUENCING OF PROSTATE CANCER CIRCULATING TUMOR CELLS AND COMPARISON WITH MATCHED CELL FREE DNA AND PROSTATE TUMORS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1269 |
0.527 |
|
| 2014 |
Hu B, Goldkorn A. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Review of Anticancer Therapy. 14: 1257-60. PMID 25199875 DOI: 10.1586/14737140.2014.957190 |
0.542 |
|
| 2014 |
Agarwal N, Dorff T, Goldkorn A. New prostate cancer drugs: extending and improving life. The Lancet. Oncology. 15: 1052-4. PMID 25104108 DOI: 10.1016/S1470-2045(14)70332-8 |
0.467 |
|
| 2014 |
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1136-42. PMID 24616308 DOI: 10.1200/Jco.2013.51.7417 |
0.476 |
|
| 2014 |
Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. Journal of the National Cancer Institute. 106: dju013. PMID 24565955 DOI: 10.1093/Jnci/Dju013 |
0.423 |
|
| 2014 |
He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. International Journal of Cancer. Journal International Du Cancer. 134: 43-54. PMID 23784558 DOI: 10.1002/Ijc.28341 |
0.609 |
|
| 2014 |
Hu BR, Fairey AS, Yang D, Li M, Groshen SG, Stephens C, Quinn DI, Kim P, Virk N, Wang L, Martin SE, Gill IS, Goldkorn A. AXIN2 and prostate cancer recurrence after radical prostatectomy. Journal of Clinical Oncology. 32: 145-145. DOI: 10.1200/Jco.2014.32.4_Suppl.145 |
0.473 |
|
| 2014 |
Dorff TB, Groshen SG, Quinn DI, Goldkorn A, Martel CL, Pinski JK, Kuhn P, Gross ME. Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: TPS5108-TPS5108. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5108 |
0.409 |
|
| 2014 |
Hu B, Xu Y, Xu T, Goldkorn A. Abstract 3997: Circulating tumor cell expression analysis using highly multiplexed qPCR to quantify a panel of 624 common cancer genes Cancer Research. 74: 3997-3997. DOI: 10.1158/1538-7445.Am2014-3997 |
0.527 |
|
| 2014 |
Rochefort HM, Xu T, Xu Y, Li M, Chen Y, Hu B, Goldkorn A. Abstract 1197: Differential gene expression analysis by RNA-seq of primary tumors, circulating tumor cells, and metastases from a mouse xenograft model of cancer dissemination Cancer Research. 74: 1197-1197. DOI: 10.1158/1538-7445.Am2014-1197 |
0.469 |
|
| 2014 |
Hu B, Fairey A, Madhav A, Xu T, Yang D, Li M, Groshen S, Stephens C, Quinn D, Kim P, Virk N, Wang L, Martin SE, Gill I, Goldkorn A. MP41-09 AXIN2 PREDICTS PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1226 |
0.481 |
|
| 2013 |
Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancers. 5: 1676-90. PMID 24305656 DOI: 10.3390/Cancers5041676 |
0.572 |
|
| 2013 |
Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 11: 416-22. PMID 24099865 DOI: 10.1016/J.Clgc.2013.07.011 |
0.52 |
|
| 2013 |
Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Lancet. Oncology. 14: 893-900. PMID 23871417 DOI: 10.1016/S1470-2045(13)70294-8 |
0.529 |
|
| 2013 |
Goldkorn A, Aparicio AM, Quinn DI. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1717-20. PMID 23798673 DOI: 10.1093/Annonc/Mdt234 |
0.476 |
|
| 2013 |
Liu SV, Dempsey PW, Strauss W, Xu Y, Xu T, Pinski JK, Dorff TB, Quinn DI, Triche TJ, Winer-Jones J, De Fusco A, McMurdie J, Goldkorn A. Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) in hormone-sensitive prostate cancer (HSPC). Journal of Clinical Oncology. 31: 11040-11040. DOI: 10.1200/Jco.2013.31.15_Suppl.11040 |
0.453 |
|
| 2013 |
Liu SV, Dempsey PW, Strauss W, Xu Y, Xu T, Winer-Jones J, Triche TJ, Quinn DI, McMurdie J, Defusco A, Goldkorn A. Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-227 |
0.474 |
|
| 2012 |
Dorff TB, Hawes D, Tsao-Wei DD, Quinn DI, Goldkorn A, Lieskovsky G, Vogelzang NJ, Groshen SG, Pinski JK. A combination herbal supplement for biochemically recurrent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 24. PMID 28142914 DOI: 10.1200/jco.2012.30.5_suppl.24 |
0.376 |
|
| 2012 |
Fairey AS, Yang D, Groshen SG, Kim P, Virk N, Wang L, Martin SE, Stephens C, Cooc J, Goldkorn A. Association between cancer stem-like cell gene expression and clinical outcome in localized prostate cancer: A nested case-control study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 31. PMID 28142907 DOI: 10.1200/jco.2012.30.5_suppl.31 |
0.476 |
|
| 2012 |
Dorff TB, Hawes D, Tsao-Wei DD, Quinn DI, Goldkorn A, Lieskovsky G, Vogelzang NJ, Groshen SG, Pinski JK. A combination herbal supplement for biochemically recurrent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 24. PMID 27967855 DOI: 10.1200/Jco.2012.30.5_Suppl.24 |
0.471 |
|
| 2012 |
Fairey AS, Yang D, Groshen SG, Kim P, Virk N, Wang L, Martin SE, Stephens C, Cooc J, Goldkorn A. Association between cancer stem-like cell gene expression and clinical outcome in localized prostate cancer: A nested case-control study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 31. PMID 27967848 DOI: 10.1200/Jco.2012.30.5_Suppl.31 |
0.554 |
|
| 2012 |
Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Molecular Cancer Therapeutics. 11: 2462-72. PMID 22933703 DOI: 10.1158/1535-7163.Mct-12-0321 |
0.366 |
|
| 2012 |
Goldkorn A, Ely B, Quinn DI, Tangen CM, Tai Y, Twardowski P, Veldhuizen PJV, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, et al. Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). Journal of Clinical Oncology. 30: 4663-4663. DOI: 10.1200/Jco.2012.30.15_Suppl.4663 |
0.549 |
|
| 2012 |
Fairey AS, Yang D, Groshen SG, Quinn DI, Kim P, Virk N, Wang L, Martin SE, Stephens C, Goldkorn A. Generation of a prognostic cancer stem-like gene expression signature in men undergoing radical prostatectomy for localized prostate cancer. Journal of Clinical Oncology. 30: 4563-4563. DOI: 10.1200/Jco.2012.30.15_Suppl.4563 |
0.502 |
|
| 2012 |
Quinn DI, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Carducci MA, Monk JP, Twardowski P, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). Journal of Clinical Oncology. 30: 4511-4511. DOI: 10.1200/Jco.2012.30.15_Suppl.4511 |
0.365 |
|
| 2012 |
Vogelzang NJ, Ely B, Fink LM, Goldkorn A, Tangen CM, Twardowski P, Veldhuizen PJV, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, et al. Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 30: 10503-10503. DOI: 10.1200/Jco.2012.30.15_Suppl.10503 |
0.534 |
|
| 2012 |
He K, Xu T, Xu Y, Kahn M, Goldkorn A. Abstract 3320: Plasticity between the cancer stem-like and non cancer stem-like states is regulated by the PI3K/Akt/β-catenin/CBP pathway Cancer Research. 72: 3320-3320. DOI: 10.1158/1538-7445.Am2012-3320 |
0.536 |
|
| 2012 |
Pinski J, Dorff TB, Hawes D, Tsao-Wei D, Quinn DI, Goldkorn A, Liskovsky G, Vogelzang N, Groshen S, Ji L. Updated Analysis of a Combination Herbal Supplement Trial in Biochemically Recurrent Prostate Cancer Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33523-7 |
0.508 |
|
| 2011 |
Piatek CI, Desai BB, Wei-Tsao D, Tang R, Acosta F, Pinski JK, Dorff TB, Goldkorn A, Jadvar H, Quinn DI. RECIST 1.0 versus 1.1: Implications for trial interpretation and design in advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2563. PMID 28022297 DOI: 10.1200/Jco.2011.29.15_Suppl.2563 |
0.496 |
|
| 2011 |
Desai BB, Quinn DI, Piatek CI, Tang R, Hu J, Goldkorn A, Gross ME, Hawes D, Jadvar H, Dorff TB. Risk stratification and stage migration effect of novel imaging and biomarker technology in men with biochemical failure after local therapy for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15196. PMID 28020991 DOI: 10.1200/Jco.2011.29.15_Suppl.E15196 |
0.447 |
|
| 2011 |
Xu Y, He K, Goldkorn A. Telomerase targeted therapy in cancer and cancer stem cells. Clinical Advances in Hematology & Oncology : H&O. 9: 442-55. PMID 21841744 |
0.568 |
|
| 2011 |
He K, Xu T, Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Molecular Cancer Therapeutics. 10: 938-48. PMID 21518726 DOI: 10.1158/1535-7163.Mct-10-1120 |
0.612 |
|
| 2011 |
Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. The Prostate. 71: 1390-400. PMID 21321978 DOI: 10.1002/Pros.21355 |
0.665 |
|
| 2011 |
Xu Y, Xu T, Cao C, Kobielak A, Goldkorn A. Abstract LB-34: Microfilter capture of live circulating tumor cells from the blood of mice bearing tumor xenografts: A new model for the study of cancer dissemination Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-34 |
0.487 |
|
| 2010 |
Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Research. 70: 6420-6. PMID 20663903 DOI: 10.1158/0008-5472.Can-10-0686 |
0.501 |
|
| 2010 |
Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Molecular Cancer Therapeutics. 9: 438-49. PMID 20124445 DOI: 10.1158/1535-7163.Mct-09-0682 |
0.474 |
|
| 2010 |
Goldkorn A, Xu T, Lu B, Williams A, Fink LM, Tangen CM, Twardowski P, Tai Y, Quinn DI, Cote R. Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps342 |
0.57 |
|
| 2010 |
Xu T, Lu B, Tai Y, Goldkorn A. Abstract LB-217: A universal cancer detection platform which measures telomerase activity from live circulating tumor cells captured on microfilter Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-217 |
0.513 |
|
| 2010 |
He K, Xu T, Goldkorn A. Abstract 5152: Cancer stem cells arise directly from differentiated cancer cells: A new model of dynamic equilibrium modulated by the Akt pathway Cancer Research. 70: 5152-5152. DOI: 10.1158/1538-7445.Am10-5152 |
0.608 |
|
| 2009 |
Xu T, Xu Y, Lao R, He K, Xue L, Goldkorn A. Mouse prostate tumor inhibition via disruption of murine telomerase: In vivo and in vitro data for a new preclinical cancer model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14631. PMID 27964180 DOI: 10.1200/Jco.2009.27.15_Suppl.E14631 |
0.503 |
|
| 2009 |
Sahu D, Xu T, Lau R, Xue L, Goldkorn A. Telomerase interference in combination with docetaxel therapy for maximal prostate cancer inhibition: In vitro data for a novel therapeutic approach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14596. PMID 27963725 DOI: 10.1200/Jco.2009.27.15_Suppl.E14596 |
0.513 |
|
| 2009 |
Goldkorn A, Xu T. Targeting prostate cancer progenitor cells with telomerase interference: A novel therapeutic strategy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22029. PMID 27963140 DOI: 10.1200/Jco.2009.27.15_Suppl.E22029 |
0.56 |
|
| 2009 |
Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology. 1: 183-205. PMID 21789121 DOI: 10.1177/1758834009349119 |
0.384 |
|
| 2009 |
Dorff T, Groshen S, Tsao-Wei D, Goldkorn A, Korn C, Quinn D, Pinski J. 7027 Interim results of a phase II trial of oxaliplatin and pemetrexed as 2nd/3rd line therapy in castration resistant prostate cancer (CRPC) European Journal of Cancer Supplements. 7: 414-415. DOI: 10.1016/S1359-6349(09)71405-3 |
0.374 |
|
| 2008 |
Dorff TB, Groshen SG, Wei D, Korn C, Goldkorn A, Quinn DI, Pinski J. Interim results of a phase II trial of pemetrexed and oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5139. PMID 27948218 DOI: 10.1200/Jco.2008.26.15_Suppl.5139 |
0.478 |
|
| 2006 |
Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Research. 66: 5763-71. PMID 16740715 DOI: 10.1158/0008-5472.Can-05-3782 |
0.36 |
|
| Show low-probability matches. |